Cart
sales@molnova.com
Ensituximab
CAS No. 1092658-06-4
Ensituximab( —— )
Catalog No. M36883 CAS No. 1092658-06-4
Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 472 | In Stock |
|
| 10MG | 757 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnsituximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnsituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
-
DescriptionEnsituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1092658-06-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. ?
molnova catalog
related products
-
3-O-Acetyl-16 alpha-...
3-O-Acetyl-16 alpha-hydroxytrametenolic acid has inhibitory activities against AAPH-induced hemolysis of red blood cells, it shows a strong inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice.
-
Sodium taurolithocho...
The major human metabolite a bile acid which inhibits radioligand binding to muscarinic M1 but not to M2 or M3 receptors.
-
Picfeltarraenin X
Picfeltarraenin X shows stronger AChE inhibition than the known AChE inhibitor Tacrine.
